These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

225 related articles for article (PubMed ID: 19859073)

  • 1. Residual microvascular risk in diabetes: unmet needs and future directions.
    Fioretto P; Dodson PM; Ziegler D; Rosenson RS
    Nat Rev Endocrinol; 2010 Jan; 6(1):19-25. PubMed ID: 19859073
    [TBL] [Abstract][Full Text] [Related]  

  • 2. How can we improve the management of vascular risk in type 2 diabetes: insights from FIELD.
    Steiner G
    Cardiovasc Drugs Ther; 2009 Oct; 23(5):403-8. PubMed ID: 19757004
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Fenofibrate: a review of its lipid-modifying effects in dyslipidemia and its vascular effects in type 2 diabetes mellitus.
    Keating GM
    Am J Cardiovasc Drugs; 2011 Aug; 11(4):227-47. PubMed ID: 21675801
    [TBL] [Abstract][Full Text] [Related]  

  • 4. "If it ain't broke, don't fix it": a commentary on the positive-negative results of the ACCORD Lipid study.
    Tenenbaum A; Fisman EZ
    Cardiovasc Diabetol; 2010 Jun; 9():24. PubMed ID: 20550659
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Therapeutic management strategies for type 2 diabetes.
    Ramesh C; Gopal V; Sembulingam K; Nappinnai M
    Curr Diabetes Rev; 2006 Aug; 2(3):339-42. PubMed ID: 18220638
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Diabetic dyslipidemia.
    Kreisberg RA
    Am J Cardiol; 1998 Dec; 82(12A):67U-73U; discussion 85U-86U. PubMed ID: 9915665
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Managing diabetic dyslipidemia: beyond statin therapy.
    Neeli H; Gadi R; Rader DJ
    Curr Diab Rep; 2009 Feb; 9(1):11-7. PubMed ID: 19192419
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effectiveness and safety of basal supported oral therapy with insulin glargine, in Japanese insulin-naive, type 2 diabetes patients, with or without microvascular complications: subanalysis of the observational, non-interventional, 24-week follow-up Add-on Lantus® to Oral Hypoglycemic Agents (ALOHA) study.
    Odawara M; Kadowaki T; Naito Y
    J Diabetes Complications; 2015; 29(1):127-33. PubMed ID: 25449981
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Fibrates and microvascular complications in diabetes--insight from the FIELD study.
    Ansquer JC; Foucher C; Aubonnet P; Le Malicot K
    Curr Pharm Des; 2009; 15(5):537-52. PubMed ID: 19199980
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Glycemic control in type 2 diabetes: from medication nonadherence to residual vascular risk.
    Giugliano D; Maiorino MI; Bellastella G; Esposito K
    Endocrine; 2018 Jul; 61(1):23-27. PubMed ID: 29322300
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The Residual Risk Reduction Initiative: a call to action to reduce residual vascular risk in patients with dyslipidemia.
    Fruchart JC; Sacks F; Hermans MP; Assmann G; Brown WV; Ceska R; Chapman MJ; Dodson PM; Fioretto P; Ginsberg HN; Kadowaki T; Lablanche JM; Marx N; Plutzky J; Reiner Z; Rosenson RS; Staels B; Stock JK; Sy R; Wanner C; Zambon A; Zimmet P
    Am J Cardiol; 2008 Nov; 102(10 Suppl):1K-34K. PubMed ID: 19068318
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Macrovascular and microvascular outcomes after beginning of insulin versus additional oral glucose-lowering therapy in people with type 2 diabetes: an observational study.
    Hall GC; McMahon AD; Carroll D; Home PD
    Pharmacoepidemiol Drug Saf; 2012 Mar; 21(3):305-13. PubMed ID: 22271442
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Glycemic control and complications in type 2 diabetes mellitus.
    Stolar M
    Am J Med; 2010 Mar; 123(3 Suppl):S3-11. PubMed ID: 20206730
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Reducing cardiovascular complications of type 2 diabetes by targeting multiple risk factors.
    Reasner CA
    J Cardiovasc Pharmacol; 2008 Aug; 52(2):136-44. PubMed ID: 18670366
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Thiazolidinediones-benefits on microvascular complications of type 2 diabetes.
    Viberti G
    J Diabetes Complications; 2005; 19(3):168-77. PubMed ID: 15866064
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Increased complications in noninsulin-dependent diabetic patients treated with insulin versus oral hypoglycemic agents: a population study.
    Savage S; Estacio RO; Jeffers B; Schrier RW
    Proc Assoc Am Physicians; 1997 Mar; 109(2):181-9. PubMed ID: 9069587
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Normalization of blood pressure and lipids in patients with diabetes].
    Clemens A; Gallwitz B
    Med Klin (Munich); 2003 Jul; 98(7):368-76. PubMed ID: 12937902
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The role of lipids in the development of diabetic microvascular complications: implications for therapy.
    Misra A; Kumar S; Kishore Vikram N; Kumar A
    Am J Cardiovasc Drugs; 2003; 3(5):325-38. PubMed ID: 14728067
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparison of risk factors of macrovascular complications. Peripheral vascular disease, cerebral vascular disease, and coronary heart disease in Japanese type 2 diabetes mellitus patients.
    Asakawa H; Tokunaga K; Kawakami F
    J Diabetes Complications; 2000; 14(6):307-13. PubMed ID: 11120454
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cross-sectional analysis of adult diabetes type 1 and type 2 patients with diabetic microvascular complications from a German retrospective observational study.
    Happich M; Breitscheidel L; Meisinger C; Ulbig M; Falkenstein P; Benter U; Watkins J
    Curr Med Res Opin; 2007 Jun; 23(6):1367-74. PubMed ID: 17559744
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.